Todd Vanderah, PhD

Co-Director, MD/PhD Dual Degree Program
Department Head, Pharmacology
Director, Comprehensive Pain and Addiction Center
Member of the Graduate Faculty
Professor, Anesthesiology
Professor, BIO5 Institute
Professor, Neurology
Professor, Neuroscience - GIDP
Professor, Pharmacology
Professor, Physiological Sciences - GIDP
Regents Professor

Contact Information

Office: 647
Building: Life Sciences North
Phone: (520) 626-7801

Email: vanderah@arizona.edu

Leadership roles: Pharmacology Executive Committee Member, Dean's Council on Faculty Affairs Director, Medical Pharmacology Graduate Program

Research Area:

Cancer Pharmacology/Biology

Neuroscience and Pain

Research Interests:

Mechanisms and pharmacology of acute and chronic models of pain; endogenous opioid systems; sensory neural systems; opioid tolerance; antinociceptive synergy between cannabinoids and opioids.

Publications

2023

Development and evaluation of a pre-clerkship spiral curriculum: data from three medical school classes.

2022

Targeting 5-HT receptors and Kv7 channels in PFC to attenuate chronic neuropathic pain in rats using a spared nerve injury model.

Extracellular Alterations in pH and K+ Modify the Murine Brain Endothelial Cell Total and Phospho-Proteome.

Angiotensin-(1-7) improves cognitive function and reduces inflammation in mice following mild traumatic brain injury.

2021

Sex hormones regulate NHE1 functional expression and brain endothelial proteome to control paracellular integrity of the blood endothelial barrier.

An underrepresented majority: A systematic review utilizing allodynic criteria to examine the present scarcity of discrete animal models for episodic migraine.

The Effects of Repeated Morphine Treatment on the Endogenous Cannabinoid System in the Ventral Tegmental Area.

The FDA Mandate to Reassess Benzodiazepines: Alprazolam Induces a Positive Conditioned Place-Preference if Male Rate

2020

Cannabinoid-2 Agonism with AM2301 Mitigates Morphine-Induced Respiratory Depression.

Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model.

Haploinsufficiency of tau decreases survival of the mouse model of Niemann-Pick disease type C1 but does not alter tau phosphorylation.

Activation of sphingosine-1-phosphate receptor subtype 1 in the central nervous system contributes to morphine-induced hyperalgesia and antinociceptive tolerance in rodents.

Potential therapeutic treatments of cancer-induced bone pain.

The Endocannabinoid System Alleviates Pain in a Murine Model of Cancer-Induced Bone Pain.

Glial neuroimmune signaling in opioid reward.

Lost in the Haze: The Physician's Role in Cannabinoid Prescribing and Advising.

Functional NHE1 expression is critical to blood brain barrier integrity and sumatriptan blood to brain uptake.

DAGLα Inhibition as a Non-invasive and Translational Model of Episodic Headache.

2019

Cdk5-mediated CRMP2 phosphorylation is necessary and sufficient for peripheral neuropathic pain.

Development and Characterization of An Injury-free Model of Functional Pain in Rats by Exposure to Red Light.

Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain.

A Novel Angiotensin-(1-7) Glycosylated Mas Receptor Agonist for Treating Vascular Cognitive Impairment and Inflammation-Related Memory Dysfunction.

Animal Models for the Study of Bone-Derived Pain.

Migraine, A Review of Basic, Clinical, Translational Approaches to New Treatment

2018

Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain.

Loss of Blood-Brain Barrier Integrity in a KCl-Induced Model of Episodic Headache Enhances CNS Drug Delivery.

Continuous remote ischemic conditioning attenuates cognitive and motor deficits from moderate traumatic brain injury.

A Kappa Opioid Receptor Agonist Blocks Bone Cancer Pain Without Altering Bone Loss, Tumor Size, or Cancer Cell Proliferation in a Mouse Model of Cancer-Induced Bone Pain.

2017

Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.

Blocking CRMP2 SUMOylation reverses neuropathic pain.

Genetic and pharmacological antagonism of NK1 receptor prevents opiate abuse potential.

Remote Ischemic Conditioning Preserves Cognition and Motor Coordination in a Mouse Model of Traumatic Brain Injury.

Homology-guided mutational analysis reveals the functional requirements for antinociceptive specificity of collapsin response mediator protein 2-derived peptides.

Long-lasting antinociceptive effects of green light in acute and chronic pain in rats.

Synergistic attenuation of chronic pain using mu opioid and cannabinoid receptor 2 agonists.

2016

Structure-Activity Relationships of [des-Arg(7)]Dynorphin A Analogues at the κ Opioid Receptor.

The cystine/glutamate antiporter system xc- drives breast tumor cell glutamate release and cancer-induced bone pain.

(S)-Lacosamide inhibition of CRMP2 phosphorylation reduces postoperative and neuropathic pain behaviors through distinct classes of sensory neurons identified by constellation pharmacology.

Enkephalin analogues with N-phenyl-N-(piperidin-2-ylmethyl)propionamide derivatives: Synthesis and biological evaluations.

Angiotensin-(1-7)/Mas receptor as an antinociceptive agent in cancer-induced bone pain.

2015

Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.

Design and synthesis of novel bivalent ligands (MOR and DOR) by conjugation of enkephalin analogues with 4-anilidopiperidine derivatives.

Discovery of Novel Multifunctional Ligands with μ/δ Opioid Agonist/Neurokinin-1 (NK1) Antagonist Activities for the Treatment of Pain.

Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.

Therapeutic potential of peroxynitrite decomposition catalysts: a patent review.

Endogenous adenosine A3 receptor activation selectively alleviates persistent pain states.

Blockade of non-opioid excitatory effects of spinal dynorphin A at bradykinin receptors.

Use of Animal Models in Understanding Cancer-induced Bone Pain.

2014

Animal models for opioid addiction drug discovery.

Discovery of amphipathic dynorphin A analogues to inhibit the neuroexcitatory effects of dynorphin A through bradykinin receptors in the spinal cord.

2013

Truncation of the peptide sequence in bifunctional ligands with mu and delta opioid receptor agonist and neurokinin 1 receptor antagonist activities.

Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.

Effect of anchoring 4-anilidopiperidines to opioid peptides.

Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.

Novel fentanyl-based dual μ/δ-opioid agonists for the treatment of acute and chronic pain.

Cancer-induced bone pain: Mechanisms and models.

2012

Repeated morphine treatment-mediated hyperalgesia, allodynia and spinal glial activation are blocked by co-administration of a selective cannabinoid receptor type-2 agonist.

Tachykinin NK₁ receptor antagonist co-administration attenuates opioid withdrawal-mediated spinal microglia and astrocyte activation.

Structure-activity relationships of trimethoxybenzyl piperazine N-type calcium channel inhibitors.

Mechanisms of Bv8-induced biphasic hyperalgesia: increased excitatory transmitter release and expression.

2011

Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.

Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain.

Intrathecal PKA-selective siRNA treatment blocks sustained morphine-mediated pain sensitization and antinociceptive tolerance in rats.

Development of potent μ and δ opioid agonists with high lipophilicity.

Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.

Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain.

2010

Sustained morphine-mediated pain sensitization and antinociceptive tolerance are blocked by intrathecal treatment with Raf-1-selective siRNA.

Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance.

Recently patented and promising ORL-1 ligands: where have we been and where are we going?

A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.

2009

Novel bifunctional peptides as opioid agonists and NK-1 antagonists.

2008

Novel D-amino acid tetrapeptides produce potent antinociception by selectively acting at peripheral kappa-opioid receptors.

Intrathecal Raf-1-selective siRNA attenuates sustained morphine-mediated thermal hyperalgesia.

Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.